Evaluation of Patients With Blood Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

898 participants

Study Classification

OBSERVATIONAL

Study Start Date

1998-04-21

Study Completion Date

2017-08-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Hematology Service provides hematology consultations for patients at the Clinical Center and participates in the training of hematology fellows. Patients with a broad range of hematologic disorders must be available in order for the senior staff of the Service to maintain clinical expertise and to provide the breadth of experience necessary for the fellowship program. The purpose of this protocol is to meet these needs by allowing the Hematology Service to see patients with a spectrum of hematologic diseases not studied on existing research protocols at the NIH. These patients will be evaluated over the course of several outpatient visits and returned to the care of their referring physicians.This study was developed to evaluate and possibly treat patients with blood disorders. The Hematology Service of the National Institutes of Health is responsible for the care of patients participating in research studies. In addition the Hematology Service also provides consultation for small groups of patients with blood disorders that have not been diagnosed or that may need special testing.

This study will also provide doctors at the NIH the opportunity to learn more about a wide range of blood disorders and conditions. Patients participating in this study will be evaluated over the course of several outpatient visits and will continue to be cared for by their regular physician.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease

NCT02394431

Sickle Cell Disease

COMPLETED

The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.

NCT00230165

Glanzmann Thrombasthenia

RECRUITING

Natural History of Sickle Cell Disease

NCT00081523

Pain Crisis

RECRUITING

Evaluation of Sickle Cell Liver Disease

NCT01950429

Sickle Cell Disease

COMPLETED

Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department

NCT02386657

Sickle Cell Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Hematology Service provides hematology consultations for patients at the Clinical Center and participates in the training of hematology fellows. Patients with a broad range of hematologic disorders must be available in order for the senior staff of the Service to maintain clinical expertise and to provide the breadth of experience necessary for the fellowship program. The purpose of this protocol is to meet these needs by allowing the Hematology Service to see patients with a spectrum of hematologic diseases not studied on existing research protocols at the NIH. These patients will be evaluated over the course of several outpatient visits and returned to the care of their referring physicians.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Disease

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The patient must have or be suspected of having a blood disorder.

The patient must be clinically stable enough for outpatient evaluation.

The patients must be referred from a physician outside the NIH who will continue to provide the patient's primary medical care.